Jun 10, 2020   SOURCE: PR NewsWire

Gastroparesis Market Analysis for the 7MM - Epidemiology and Forecasts to 2028

DUBLIN, June 10, 2020 /PRNewswire/ -- The "Gastroparesis Market Insights, Epidemiology, and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Gastroparesis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Gastroparesis, Gender - Specific Prevalence of Gastroparesis, Severity - Specific Prevalence of Gastroparesis, Type - Specific Prevalence of Gastroparesis, and Total Diagnosed Prevalent Population of Gastroparesis] scenario of Gastroparesis in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2028.

This analysts have assessed that the total prevalent population of Gastroparesis in the 7MM was 33,690,400 in 2017. In addition to this, it was assessed that the total diagnosed prevalent population of Gastroparesis in the 7MM was assessed to be 16,845,200 in 2017.

The market size of Gastroparesis in seven major markets was estimated to be USD 3,414.16 million in 2017. The United States accounts for the highest market size of Gastroparesis,i.e. USD 1,558.41 million, in comparison to the other major markets i.e., EU5 countries and Japan. Among the EU5 countries, Germany had the highest market size in 2017, while the UK had the lowest market size of Gastroparesis in 2017.

With the launch of emerging therapies like Gimoti (EVK - 001, a product of Evoke Pharma), which is a metoclopramide nasal spray, Relamorelin (Allergan), Tradipitant (Vanda Pharmaceuticals), Velusetrag (Theravance Biopharma), and CIN - 102 (Deuterated Domperidone, CinRX Pharma), the market for Gastroparesis is anticipated to change during the forecast period (2019 - 2028).

Products that are anticipated to be launched during the forecast period are in late clinical stages of development, while others are in ongoing late clinical development stages. Some of the above-mentioned drug candidates have shown very promising results and it has been anticipated by the analysts that completion of clinical development and launch of these products in the market, might increase the market share of these companies, and besides this, patients of Gastroparesis will have better management practices.

According to this assessment, potential emerging candidates shall launch in the upcoming years of the forecast period [2019 - 2028], and with their anticipated launch, the market size of Gastroparesis will also experience significant growth.

Gastroparesis Report Insights

    --  Total Prevalence of Gastroparesis
    --  Gender - Specific Prevalence of Gastroparesis
    --  Severity - Specific Prevalence of Gastroparesis
    --  Type - Specific Prevalence of Gastroparesis
    --  Total Diagnosed Prevalent Population of Gastroparesis
    --  Therapeutic Approaches
    --  Pipeline Analysis
    --  Market Size and Trends
    --  Market Opportunities
    --  Impact of upcoming Therapies

Gastroparesis Report Key Strengths

    --  10 - Year Forecast
    --  7MM Coverage
    --  Epidemiology Segmentation
    --  Drugs Uptake
    --  Highly Analyzed Market
    --  Key Cross Competition

Gastroparesis Report Assessment

    --  Current Treatment Practices
    --  Unmet Needs
    --  Detailed Pipeline Product Profiles
    --  Market Attractiveness
    --  Market Drivers and Barriers

Key Topics Covered:

1. Key Insights

2. Gastroparesis: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Gastroparesis in 2017
2.2. Total Market Share (%) Distribution of Gastroparesis in 2028

3. Gastroparesis: Disease Background and Overview
3.1. Introduction
3.2. Types of Gastroparesis: Based on Causes
3.3. Clinical Signs and Symptoms
3.4. Mechanisms or Pathophysiology of Gastroparesis
3.5. Diagnosis of Gastroparesis

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalence of Gastroparesis in the 7MM
4.3. Type-Specific Prevalence of Gastroparesis in the 7MM
4.4. Gender-Specific Prevalence of Gastroparesis in the 7MM
4.5. Severity Specific Prevalence of Gastroparesis in the 7MM
4.6. Total Diagnosed Prevalent Population of Gastroparesis in the 7MM

5. United States Epidemiology

6. EU5 Epidemiology

7. Japan Epidemiology

8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Treatment Algorithm for Gastroparesis
8.2. Treatment and Management for Gastroparesis

9. Proposed Clinical Guidelines for the Management of Gastroparesis
9.1. Recommendations
9.2. Consensus Guidelines for Clinical Management of Diabetic Gastroparesis

10. Unmet Needs

11. Marketed Products
11.1. Reglan: ANI Pharmaceuticals
11.2. Motilium (Domperidone): Janssen

12. Emerging Therapies
12.1. Key Cross Competition
12.2. Relamorelin: Allergan
12.3. Gimoti (Metoclopramide Nasal Spray): Evoke Pharma
12.4. Tradipitant: Vanda Pharmaceuticals
12.5. Velusetrag: Theravance Biopharma
12.6. CNSA-001: Censa Pharmaceuticals
12.7. Nimacimab: Bird Rock Bio
12.8. CIN-102: CinDome Pharma
12.9. TAK 906: Takeda (Millennium Pharmaceuticals)

13. Gastroparesis: Seven Major Market Analysis

14. United States: Market Outlook

15. EU-5 countries: Market Outlook

16. Japan Market Outlook

17. Market Drivers

18. Market Barriers

19. Appendix

Companies Mentioned 

    --  CinDome Pharma
    --  Takeda (Millennium Pharmaceuticals)
    --  Evoke Pharma
    --  Vanda Pharmaceuticals
    --  Theravance Biopharma
    --  ANI Pharmaceuticals
    --  Janssen
    --  Allergan
    --  Censa Pharmaceuticals
    --  Bird Rock Bio

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/yg22bk

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/gastroparesis-market-analysis-for-the-7mm---epidemiology-and-forecasts-to-2028-301073550.html

SOURCE Research and Markets